Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00334282 · OUTCOME

Time to Response as Assessed by an Independent Review Committee (IRC) and the Investigator

Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma · Source last updated 2016-02-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
weeks
Interval / dispersion
95% Confidence Interval
Time frame
Randomization until CR or PR (assessed for up to 2 years)

What was measured

Time to response is defined as the time from randomization until the first documented evidence of complete response (all detectable tumor has disappeared) or partial response (a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the Baseline sum) (whichever status was recorded first).

Analysis population: ITT Population. Only participants with a complete or partial response were analyzed. Only results for pazopanib are given because there were not enough placebo responders. The different number of participants analyzed is due to differences in clinical judgement, measurement, and the selection of target lesions.

Groups in this outcome

Pazopanib 800 mg

Pazopanib 800 mg (tablets) administered orally once a day

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg103

Reported measurements

IRC assessed, n=88
Values in weeks · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg11.9Not reported9.412.3Not reported
Investigator assessed, n=103
Values in weeks · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg12.0Not reported11.612.3Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        9.4
        upper Limit
        12.3
        value
        11.9
    title
    IRC assessed, n=88
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        11.6
        upper Limit
        12.3
        value
        12.0
    title
    Investigator assessed, n=103
denoms
  1. counts
    1. group Id
      OG000
      value
      103
    units
    Participants
description
Time to response is defined as the time from randomization until the first documented evidence of complete response (all detectable tumor has disappeared) or partial response (a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the Baseline sum) (whichever status was recorded first).
dispersion Type
95% Confidence Interval
groups
  1. description
    Pazopanib 800 mg (tablets) administered orally once a day
    id
    OG000
    title
    Pazopanib 800 mg
param Type
MEDIAN
population Description
ITT Population. Only participants with a complete or partial response were analyzed. Only results for pazopanib are given because there were not enough placebo responders. The different number of participants analyzed is due to differences in clinical judgement, measurement, and the selection of target lesions.
reporting Status
POSTED
time Frame
Randomization until CR or PR (assessed for up to 2 years)
title
Time to Response as Assessed by an Independent Review Committee (IRC) and the Investigator
type
SECONDARY
unit Of Measure
weeks

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice